Replies to post #322521 on NorthWest Biotherapeutics Inc (NWBO)

[survivor1x]

It was confirmed that ATL(Autologous Tumor Lysate) is DCVAX. Along with POLY ICLC

https://clinicaltrials.gov/ct2/show/NCT04201873

[flipper44]

sharpie510 Tuesday, 08/25/20 03:49:24 PM

Post # 302089
I wrote to Sichen Li, one of the sponsor contacts, early this year. I asked her if ATL-DC was DCVax-L but just a generic name for it.

I asked:
Quote:
Is this trial using DCVax-L as part of the protocol? What is ATL-DC? Is that just the generic term for DCVax-L? Thanks again.
She replied:
Quote:
Yes to all your questions.
I'm satisfied that if this trial shows ATL-DC is efficacious in rGBM (either as a monotherapy or in combination with pembrolizumab), DCVax-L will be the beneficiary. Also note that this trial also uses the generic name pembrolizumab instead of Keytruda.

I think Senti also asked a UCLA rep at some gathering in SoCal a few months ago and essentially got the same answer

[ATLnsider]

Here is another connection between NWBio and ATL-DC:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568250/#!po=1.42857

This study compared autologous tumor lysate (ATL) loading of dendritic cells (DC), with dendritic cells loaded with synthetic glioma-associated antigen (GAA) peptides, in malignant glioma patients.

Look down at the acknowledgments at the bottom of the page. This study was funded in part by the National Institutes of Health (NIH), the National Cancer Institute (NCI) and Northwest Biotherapeutics. This study concluded that ATL-DC (DCVax-L) vaccination may induce a more heterogeneous and diverse anti-tumor immune response against malignant glioma.

ATL-DC is the version of DCVax-L that is made on site at UCLA. It is not the branded version.that is made by Cognate or Advent Bioservices.